freeline
present
new
data
annual
protein
antibody
engineering
summit
updated
data
analytical
technologies
determining
proportion
aav
capsids
containing
vector
genomes
potentially
increasing
safety
efficacy
freeline
aav
delivery
model
london
globe
newswire
freeline
therapeutics
holdings
plc
nasdaq
frln
company
freeline
fully
integrated
next
generation
systemic
gene
therapy
company
ambition
transforming
lives
patients
suffering
inherited
systemic
debilitating
diseases
today
announced
new
data
analytical
technologies
determining
proportion
viruses
aav
capsids
containing
vector
genomes
presented
annual
protein
antibody
engineering
summit
pegs
november
freeline
present
updated
data
use
analytical
technologies
determining
proportion
aav
capsids
containing
vector
genomes
including
use
panel
assays
combination
methodologies
fully
characterise
aav
product
ratio
discussed
important
quality
attribute
aavs
potential
impact
safety
efficacy
pleased
report
additional
data
analytical
technologies
said
theresa
heggie
ceo
freeline
therapeutics
announcement
comes
final
quarter
pivotal
year
freeline
strengthened
balance
sheet
following
successful
launch
ipo
continued
progress
clinical
programmes
haemophilia
b
fabry
disease
well
advancements
preclinical
programmes
gaucher
disease
haemophilia
always
ambition
produce
capsid
technologies
allow
us
potentially
increase
safety
efficacy
across
platform
benefit
title
analytical
technologies
determining
proportion
aav
capsids
containing
vector
genomes
presenter
sonya
schermann
director
analytical
development
freeline
freeline
freeline
biotechnology
company
focused
gene
therapy
targeting
liver
vision
create
better
lives
people
suffering
chronic
systemic
diseases
using
potential
gene
therapy
treatment
provide
potential
functional
cure
freeline
headquartered
uk
operations
germany
us
statements
press
release
contains
statements
constitute
forward
looking
statements
term
defined
united
states
private
securities
litigation
reform
act
including
statements
express
company
opinions
expectations
beliefs
plans
objectives
assumptions
projections
regarding
future
events
future
results
contrast
statements
reflect
historical
facts
examples
include
discussion
company
strategies
financing
plans
clinical
trial
plans
cases
identify
statements
terminology
anticipate
intend
believe
estimate
plan
seek
project
expect
may
would
could
negative
terms
similar
expressions
forward
looking
statements
based
management
current
beliefs
assumptions
information
currently
available
company
place
undue
reliance
statements
statements
subject
many
risks
uncertainties
including
company
recurring
losses
operations
development
company
product
candidates
including
statements
regarding
timing
initiation
completion
outcome
clinical
studies
trials
related
preparatory
work
company
ability
design
implement
successful
clinical
trials
product
candidates
potential
pandemic
epidemic
outbreak
infectious
diseases
eu
including
pandemic
disrupt
company
clinical
trial
pipeline
company
failure
demonstrate
safety
efficacy
product
candidates
fact
results
obtained
earlier
stage
clinical
testing
may
indicative
results
future
clinical
trials
company
ability
enroll
patients
clinical
trials
product
candidates
possibility
one
company
product
candidates
may
cause
serious
adverse
undesirable
unacceptable
side
effects
properties
could
delay
prevent
regulatory
approval
limit
commercial
potential
company
ability
obtain
maintain
regulatory
approval
product
candidates
company
limited
manufacturing
experience
could
result
delays
development
commercialization
product
candidates
company
ability
identify
discover
additional
product
candidates
failure
capitalize
programmes
product
candidates
risks
uncertainties
may
cause
statements
inaccurate
readers
cautioned
place
undue
reliance
statements
many
risks
outside
company
control
could
cause
actual
results
differ
materially
thought
would
occur
statements
included
press
release
made
date
hereof
company
undertake
specifically
declines
obligation
update
statements
publicly
announce
results
revisions
statements
reflect
future
events
developments
except
required
law
information
please
reference
company
reports
documents
filed
securities
exchange
commission
may
get
documents
visiting
edgar
sec
website
information
jw
communications
julia
wilson
juliawilsonuk
